NOXXON Pharma N : enrolls last brain cancer patient in dose escalation portion of GLORIA study and confirms phase 1/2 read-out in Q1 2022

NOXXON ENROLLS LAST BRAIN CANCER PATIENT IN DOSE ESCALATION


PORTION OF GLORIA STUDY AND


CONFIRMS PHASE 1/2 READ-OUT IN Q1 2022

... | September 22, 2021

Related Keywords

Germany ,Paris ,France General ,France ,Berlin ,Ulf Jungnelius ,Pharmanv Euronext ,Newcap Arthur Rouill ,Guillaume Van Renterghem , ,Euronext Growth Paris ,Jarl Ulf Jungnelius ,Senior Medical Advisor ,Executive Officer ,Media Relations ,Cap Arthur Rouill ,ஜெர்மனி ,பாரிஸ் ,பிரான்ஸ் ,பெர்லின் ,நிர்வாகி அதிகாரி ,மீடியா உறவுகள் ,Noxxon Pharmanv Stock Exchange ,News ,Information ,Press Release ,Noxxon ,Enrolls ,Mast ,Rain ,Dancer ,Patient ,N ,Nose ,Portion ,F ,Gloria ,Study ,Onfirms ,Hase ,1 Alnox Nl0012044762 ,